Join our daily newsletter At The Bell to receive exclusive market insights
The Recce 327 Topical Gel is “highly effective” for treating infected burn wounds – and it works quickly too – Recce Pharmaceuticals (ASX:RCE) confirmed in ongoing tests, setting the stage for a U.S. Defence partnership.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This content is disseminated in partnership with Recce. It is intended to inform investors and should not be taken as a recommendation or financial advice.
While a pivot into State-side defence may be surprising for some Recce shareholders, it forms part of a larger strategy that the company is very confident will yield promising results relatively shortly.
The biotech player’s confidence boils down to one thing: It’s “superior” to other options.
“Our compound is statistically significant in its ability to reduce the infections above and beyond the existing forms of treatment, and statistically superior to be able to close those infections or have wound healing,” Recce’s CEO, James Graham, told HotCopper in a Watchlist interview soon after the release.
“It’s a very, very complicated space, and so this is very promising,” he added.
More market news
Gov’t help: Oz likely to get commodity supports, but don’t expect Trumpian flair
All-time rise: XJO hits new ATH on RBA cut – is 9,000 by EOY too low?
With these results in pocket, RCE is now looking to use its “new hope” to partner with the U.S. Department of Defence and secure more windfall grants; that U.S. defence arm has been calling for companies to help in the space.
There’s a track record set here, too: Recce previously netted a $2M U.S. Army grant.
Join the discussion. See what HotCopper users are saying about Recce Pharmaceuticals Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
